Enclomiphene
The active isomer of clomiphene, a selective estrogen receptor modulator (SERM) that raises testosterone while preserving fertility. Not FDA-approved as a standalone drug, but widely available through compounding pharmacies.
Enclomiphene is the purified active half of Clomid — a small-molecule SERM, not a peptide — used off-label to raise testosterone without shutting down fertility the way TRT does. It works only in secondary hypogonadism, where the testes still respond to LH and FSH, so a baseline LH/FSH draw is the non-negotiable first step. Evidence is real but narrower than the marketing: pooled SERM data show roughly +274 ng/dL testosterone with preserved gonadotropins, and enclomiphene raises estradiol less than racemic clomiphene does — though the class still raises estradiol substantially versus placebo. It is not FDA-approved (Androxal got a Complete Response Letter in 2015 and was shelved in 2021), supply is entirely compounded, the UK's sexual medicine society recommends against routine use outside specialist care, and WADA prohibits it at all times under S4.2.
What is Enclomiphene?
Enclomiphene is the trans-isomer of clomiphene citrate — the "active" half of Clomid that stimulates testosterone production. Unlike exogenous testosterone (TRT), which shuts down the body's own production and can cause infertility, enclomiphene works by blocking estrogen receptors in the hypothalamus, tricking the brain into producing more LH and FSH, which in turn stimulate the testes to make more testosterone and sperm. It is technically not a peptide — it's a small-molecule SERM — but it is widely discussed in the peptide and hormone optimization community as a fertility-preserving alternative to TRT. Enclomiphene was developed as Androxal by Repros Therapeutics, but FDA approval was denied in 2015 and development was discontinued in 2021. It remains available through compounding pharmacies under Section 503A: enclomiphene citrate is in FDA's 503A category 1 (bulk drug substances under evaluation, May 14, 2026 list), and FDA does not intend to take action against pharmacies that compound with category 1 substances, provided the guidance's conditions are met.
What Enclomiphene Is Investigated For
Enclomiphene is investigated primarily for testosterone restoration in men with secondary hypogonadism, fertility preservation as a TRT alternative, and post-cycle therapy after anabolic steroid use. The strongest evidence is a 2025 systematic review and meta-analysis of 10 RCTs (819 patients) confirming SERM-mediated increases of ~274 ng/dL in total testosterone with preserved LH and FSH — i.e., stimulated endogenous production rather than suppression — and a 2024 retrospective comparison in 66 men (Saffati et al., PMID 39434750) in which enclomiphene produced substantially lower estradiol elevation than clomiphene (-5.92 vs +17.50 pg/mL, p=0.001) and 82% lower ODDS of adverse events (OR 0.18, 95% CI 0.07-0.44). Two cautions about that study are usually dropped: its testosterone comparison was not statistically significant (median +166 vs +98 ng/dL, p=0.20), and it was a sequential design in which the same patients took clomiphene first and then enclomiphene, using their clomiphene levels as the new baseline — not a randomized head-to-head. A July 2026 systematic review and meta-analysis of clomiphene versus TRT (Constantinou et al., Eur J Clin Pharmacol, PMID 42435198) found no significant difference in serum testosterone between clomiphene and testosterone gel, but reported LOWER post-treatment libido scores with clomiphene than with TRT (MD -0.54, p=0.009). It studied racemic clomiphene rather than enclomiphene and measured no cardiovascular, bone or metabolic endpoints, so it does not settle the equivalence question. The honest caveats are threefold: enclomiphene is technically a small-molecule SERM rather than a peptide (included here because of how frequently it is discussed in peptide and hormone-optimization communities); it is not FDA-approved after Repros Therapeutics received a Complete Response Letter in 2015 and development was discontinued in 2021; and it is effective only in secondary hypogonadism, not primary testicular failure, where the testes cannot respond to elevated LH/FSH signaling. Long-term safety beyond 2–3 years and cardiovascular/bone-density equivalence to TRT remain incompletely established, and an August 2026 Cureus case report of newly detected atrial flutter after enclomiphene dose escalation (Tariq et al., PMID 42741668) is the first enclomiphene-specific cardiovascular adverse-event report in the modern literature. It should be read carefully rather than loudly: the authors' own Naranjo assessment rated causality only as possible, the patient had a prior mitral valve repair and echocardiographic atrial and ventricular remodelling that the authors describe as a substrate sufficient on its own to sustain macro-reentrant atrial flutter, the escalation was an inadvertent increase from 25 to 50 mg daily, and the paper states plainly that causality cannot be established.
History & Discovery
A caveat up front: enclomiphene is not a peptide. It is a small-molecule selective estrogen receptor modulator — a triphenylethylene compound, structurally related to tamoxifen — and it appears on this site because the peptide and hormone-optimization communities discuss it constantly as a fertility-preserving alternative to testosterone replacement. Users searching for trusted peptide-adjacent information expect to find it covered, so we cover it while being clear about the chemistry. Clomiphene citrate (Clomid) was approved by the FDA in 1967 for female ovulation induction in anovulatory infertility. It is a mixture of two stereoisomers: enclomiphene (the trans, anti-estrogenic isomer, roughly 62% of the racemate) and zuclomiphene (the cis, weakly estrogenic and slowly-cleared isomer, roughly 38%). Male off-label use of clomiphene for secondary hypogonadism emerged in the urology and reproductive-endocrinology literature over subsequent decades, based on the same HPG-axis mechanism: block estrogen-mediated negative feedback at the hypothalamus, raise LH and FSH, stimulate endogenous testosterone and spermatogenesis, preserve fertility. Repros Therapeutics advanced purified enclomiphene as Androxal specifically for secondary hypogonadism in men, aiming to strip out the long-half-life zuclomiphene isomer responsible for much of clomiphene's side effect and estradiol-elevation profile. Phase 3 trials demonstrated testosterone normalization with preserved gonadotropins and sperm counts. The FDA issued a Complete Response Letter in 2015, citing questions about the Phase 3 trial design rather than safety or efficacy failures per se. Repros did not secure the additional trials before Allergan acquired the company in 2017, and the Androxal program was discontinued in 2021. Enclomiphene thus occupies an unusual position: clinically credible, mechanistically well-supported, and FDA-unapproved for its primary indication — yet widely available through compounding pharmacies under Section 503A, because enclomiphene citrate sits in FDA's 503A category 1 (substances under evaluation), which FDA's interim policy allows pharmacies to compound with while it decides whether to add them to the 503A bulks list.
How It Works
Enclomiphene blocks estrogen receptors in the brain's hypothalamus. Normally, estrogen signals the brain to slow down testosterone production. By blocking that signal, enclomiphene tricks the brain into thinking estrogen is low, causing it to release more LH and FSH — the hormones that tell the testes to produce more testosterone and sperm.
Enclomiphene is a selective estrogen receptor modulator (SERM) that competitively antagonizes estrogen receptor alpha (ERα) in the hypothalamus. By blocking estrogen-mediated negative feedback on GnRH neurons, it increases pulsatile GnRH secretion, leading to elevated LH and FSH release from the anterior pituitary. LH stimulates Leydig cell testosterone synthesis; FSH supports Sertoli cell function and spermatogenesis. Unlike exogenous testosterone, this preserves the hypothalamic-pituitary-gonadal (HPG) axis and maintains intratesticular testosterone concentrations necessary for sperm production. A meta-analysis of 10 RCTs (819 patients) showed SERMs increased total testosterone by 273.76 ng/dL, LH by 4.66 IU/L, and FSH by 4.59 IU/L vs placebo. Compared to testosterone gel, SERMs produced comparable testosterone levels with significantly higher LH and FSH — indicating preserved endogenous production rather than suppression. Those pooled figures come from the SERM class as a whole, combining clomiphene and enclomiphene trials. The enclomiphene-versus-clomiphene contrast is a separate and weaker source: a 66-patient retrospective sequential comparison (Saffati et al. 2024, PMID 39434750) in which enclomiphene showed lower estradiol change than clomiphene (-5.92 vs +17.50 pg/mL, p=0.001) and 82% lower odds of adverse events (OR 0.18, 95% CI 0.07-0.44), with no significant difference in testosterone (p=0.20). Worth noting against the common framing of enclomiphene as estradiol-neutral: in the same 10-RCT meta-analysis, SERM therapy raised estradiol substantially against placebo at the class level (MD +33.99 pg/mL, 95% CI 19.19-48.79). Enclomiphene raises estradiol less than racemic clomiphene does, not less than baseline.
Evidence Snapshot
Human Clinical Evidence
Moderate. A 2025 systematic review and meta-analysis of 10 RCTs (819 patients) confirmed SERMs increase testosterone by ~274 ng/dL with preserved FSH/LH (Archives of Endocrinology and Metabolism). A 2024 retrospective sequential comparison (66 patients, Translational Andrology and Urology) found enclomiphene produced significantly lower estradiol elevation than clomiphene (-5.92 vs +17.50 pg/mL) and 82% lower odds of adverse events (OR 0.18, 95% CI 0.07-0.44), though its testosterone difference did not reach significance (p=0.20) and the design was not randomized. The foundational dose-ranging evidence is older: a 48-man Phase II study comparing enclomiphene at 6.25, 12.5 and 25 mg daily against transdermal testosterone (Wiehle and Cunningham, BJU Int 2013, PMID 23875626). Multiple Phase 2/3 trials demonstrated testosterone normalization while preserving sperm counts. FDA approval was denied due to study design concerns, not safety or efficacy failures.
Animal / Preclinical
Limited — enclomiphene's mechanism is well-established from decades of clomiphene research. The clinical evidence base is the primary support.
Mechanistic Rationale
Strong. Hypothalamic estrogen receptor antagonism → increased GnRH → LH/FSH → testosterone is a well-validated endocrine pathway. The advantage of enclomiphene over racemic clomiphene (removing the estrogenic zuclomiphene isomer) is mechanistically straightforward and clinically confirmed.
Research Gaps & Open Questions
What the current literature has not yet settled about Enclomiphene:
- 01Long-term safety beyond 2–3 years — Phase 3 and open-label extension data extend to roughly this window; true long-term cardiovascular, bone density, and metabolic safety data are thinner than for TRT.
- 02Cardiovascular and bone density equivalence to TRT remains genuinely open, and recent publications have not closed it despite often being cited as though they had. The July 2026 Constantinou meta-analysis (PMID 42435198) compares clomiphene with TRT on serum testosterone, other hormonal parameters and libido — it reports no cardiovascular, bone or metabolic endpoints at all, and it studies racemic clomiphene rather than enclomiphene. The July 2026 Tadisina analysis (PMID 42015850) is a retrospective US Veterans cohort on clomiphene citrate, also without enclomiphene. No trial has tested whether enclomiphene-raised testosterone delivers the skeletal or cardiovascular benefits that exogenous testosterone does.
- 03Optimal dose-response — the 12.5 vs. 25 mg daily question has been partially addressed, but individualized dose titration guidance based on genotype, BMI, or baseline HPG reserve is underdeveloped.
- 04PCT efficacy in post-steroid users is not supported by controlled clinical trials, and the 2026 reviews that are sometimes cited as supportive in fact argue the opposite. Bandura et al. (Andrology, PMID 42387872) state that no standardized treatment exists, that post-cycle therapy is largely pursued through unsupervised use, and that clomiphene's clinical efficacy, safety and optimal monitoring in this setting remain poorly defined. Smit et al. (Endocr Connect, PMID 42644333) note that PCT is generally not recommended academically because benefits are uncertain and risks real, and that spontaneous recovery occurs in most individuals within months of cessation. The reviews consolidate the mechanistic rationale while explicitly declining to endorse the practice.
- 05Effects in older men with age-related testosterone decline — most Phase 3 trial enrollment centered on younger-to-middle-aged men with documented secondary hypogonadism; efficacy and safety in men over 65 with age-related decline is less well characterized.
- 06Compounded vs. sponsor-product equivalence — since the sponsor product (Androxal) never reached market, the real-world supply is entirely compounded, with the quality-variability concerns that implies.
- 07The correct dose ceiling is unsettled, and the sources now openly disagree. Most consumer-facing guidance treats 25 mg daily as the practical maximum, while the 2026 British Society of Sexual Medicine position statement (PMID 41714894) describes titrating from 6.25 mg weekly up to 25 mg and, where response is inadequate, as far as 50 mg daily. No trial has compared those ceilings for efficacy or safety, which matters because the one published cardiovascular case report involved an inadvertent escalation from 25 to 50 mg.
- 08Whether enclomiphene's testosterone gains translate into the symptomatic outcomes people actually want is less established than the hormone data suggest. The 2026 clomiphene-versus-TRT meta-analysis found libido scores significantly LOWER on clomiphene than on testosterone despite comparable serum testosterone (PMID 42435198) — a dissociation between biochemical and symptomatic response that the enclomiphene literature has not addressed.
Forms & Administration
Enclomiphene is taken as a once-daily oral capsule, typically 12.5-25 mg. It is available through compounding pharmacies with a prescription. Baseline and follow-up bloodwork (total testosterone, free testosterone, estradiol, LH, FSH, CBC) is recommended. All medications should only be used under the guidance of a qualified healthcare provider.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
12.5–25 mg once daily orally is the most commonly described protocol, tracing back to the Phase II dose-ranging study that tested 6.25, 12.5 and 25 mg daily against transdermal testosterone (Wiehle and Cunningham, BJU Int 2013, PMID 23875626) and carried forward into the Androxal programme and current compounding practice. Note that clinical guidance now runs higher than the consumer consensus: the 2026 British Society of Sexual Medicine position statement describes starting at 6.25 mg daily, titrating weekly as tolerated to 25 mg, and going to 50 mg daily where the clinical or biochemical response is inadequate (PMID 41714894). Some clinicians use 12.5 mg daily or 25 mg every other day for long-term maintenance once testosterone targets are reached. Doses above 25 mg daily are uncommon in consumer practice and have been described as offering little additional testosterone response for added side-effect risk, but that ceiling is a convention rather than a trial result, and the BSSM explicitly contemplates 50 mg in non-responders. The one published cardiovascular case report followed an inadvertent escalation from 25 to 50 mg, which is an argument for supervising any move above 25 mg rather than an argument that the higher dose is inherently unsafe.
Frequency
Once daily, typically in the morning. Unlike TRT, it is a daily oral medication rather than a weekly injection or gel.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
For secondary hypogonadism, enclomiphene is often used continuously as long as the underlying indication persists. In post-cycle therapy (PCT) contexts after exogenous androgen use, protocols typically run 4–8 weeks to restart HPG axis function, with tapering. The Phase 3 trials ran 3–6 months with open-label extensions; long-term safety data beyond 12–24 months of continuous use is thinner.
Protocol Notes
Baseline labs before starting typically include total and free testosterone, estradiol (sensitive assay), LH, FSH, SHBG, CBC (for hematocrit baseline), and a lipid panel. Follow-up labs at 4–8 weeks confirm response and identify over-responders (testosterone above 1,000 ng/dL) or non-responders (likely primary hypogonadism, where enclomiphene will not work because the testes cannot respond to elevated LH/FSH). Because enclomiphene works upstream of the testes, it is ineffective in primary hypogonadism (testicular failure) — the distinguishing pre-treatment assessment is the LH/FSH pattern on baseline labs. Low testosterone with low or inappropriately normal LH/FSH (secondary) is the right indication; low testosterone with high LH/FSH (primary) is not. Estradiol rises less than on racemic clomiphene but is far from zero, and this is routinely undersold. In the pooled 10-RCT meta-analysis, SERM therapy raised estradiol by a mean 33.99 pg/mL against placebo at the class level (95% CI 19.19-48.79); the enclomiphene-versus-clomiphene data show a relative advantage (-5.92 vs +17.50 pg/mL change), not an absence of estrogenic effect. Users prone to gynecomastia or emotional sensitivity to estradiol changes should monitor. Visual symptoms (shimmering, floaters) are rare with enclomiphene compared to clomiphene but are the class signal that would warrant discontinuation and ophthalmologic evaluation. Compounded product quality varies. Third-party-tested pharmacies and those with robust USP compliance are the reasonable floor. Research-chemical sources marketed online are not appropriate.
Enclomiphene is not FDA-approved as a standalone drug for any indication. It is available through compounding pharmacies under an individualized prescription. Use in men for testosterone support, in PCT contexts, or in any other indication is off-label. Racemic clomiphene (Clomid) is FDA-approved for female ovulation induction; male use of either compound is off-label.
Timeline of Effects
Onset
LH and FSH rise within days of starting daily dosing. Testosterone typically begins to rise within 1–2 weeks, with meaningful increases detectable on labs at 4 weeks. Subjective effects (energy, libido, mood, morning erections) are commonly reported in the 2–6 week window though lag behind the biochemical changes.
Peak Effect
Testosterone typically plateaus in the 6–12 week range on stable dosing, with the range depending on individual HPG reserve and baseline suppression. Phase 3 trials described average total testosterone increases of ~274 ng/dL at standard doses. Sperm count and quality effects develop over a full spermatogenic cycle (~3 months).
After Discontinuation
On discontinuation, LH/FSH return toward baseline within 1–2 weeks, and testosterone follows. For patients who had meaningful endogenous HPG reserve and were using enclomiphene to overcome functional suppression (e.g., obesity-related hypogonadism that has been addressed by weight loss), some patients hold improved testosterone after cessation. For those using it primarily as an alternative to TRT without addressing underlying drivers, testosterone typically returns to pre-treatment levels within 1–2 months.
Monitoring & Measurement
Bloodwork & Labs
- •Total and free testosterone — the primary endpoint; target range typically 600–900 ng/dL total
- •LH and FSH — rise before testosterone does, making them the earliest signal of response
- •Estradiol via sensitive LC-MS/MS assay — rises in parallel with testosterone; problematic above ~40 pg/mL with symptoms
- •SHBG — interprets free testosterone
- •Lipid panel — SERMs can shift HDL modestly
- •CBC with hematocrit — for comparison with injectable TRT, which frequently raises hematocrit; enclomiphene rarely does
Functional & Performance Tests
- •Subjective libido, energy, and mood tracking — the symptomatic outcomes that motivate most use
When to Test
Baseline, 6 weeks, and 12 weeks.
Interpretation & Notes
Enclomiphene raises endogenous testosterone by blocking estradiol feedback at the hypothalamus. The response sequence is predictable: LH and FSH rise within 2–4 weeks, total testosterone follows within 6–8 weeks, and estradiol climbs in parallel with testosterone. The target is total testosterone 600–900 ng/dL with estradiol under roughly 40 pg/mL and no symptoms of high E2 (nipple tenderness, water retention, mood effects). Unlike injectable TRT, hematocrit rarely rises to problematic levels, but an annual CBC is still sensible. The rare visual-disturbance signal from the SERM class (shimmering, floaters) warrants stopping and a clinician visit if it appears. Labs available direct-to-consumer via LabCorp, Quest, Marek Health, and Ulta Lab Tests.
Common Questions
How is enclomiphene different from clomiphene (Clomid)?
Clomiphene contains two isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene is an estrogen agonist with a long half-life that accumulates over time, contributing to side effects like mood changes, visual disturbances, and elevated estradiol. Enclomiphene is the pure anti-estrogenic isomer — it raises testosterone with significantly fewer adverse effects and lower estradiol elevation.
Why isn't enclomiphene FDA-approved?
Repros Therapeutics submitted enclomiphene (as Androxal) for FDA approval, but received a Complete Response Letter in 2015. The FDA determined the Phase 3 study design was no longer adequate and requested additional trials. After Allergan acquired Repros in 2017, development was discontinued in 2021. The studies were never completed — it's a business decision, not a safety issue.
Can enclomiphene replace TRT?
For secondary hypogonadism (where the problem is in the brain's signaling, not the testes themselves), enclomiphene can meaningfully raise testosterone — a meta-analysis showed an average increase of ~274 ng/dL. It preserves fertility and sperm production, unlike TRT. However, for primary hypogonadism (testicular failure), enclomiphene won't work because the testes can't respond to the increased LH/FSH signal.
How do I know whether I have secondary or primary hypogonadism?
Baseline LH and FSH on a morning blood draw are the distinguishing test. Low testosterone paired with low or inappropriately normal LH/FSH indicates secondary hypogonadism (a signaling problem in the hypothalamus or pituitary), which is the indication where enclomiphene works. Low testosterone paired with elevated LH/FSH indicates primary hypogonadism (the testes themselves are failing), where enclomiphene will not meaningfully raise testosterone because the testes cannot respond to the elevated gonadotropin signal. This pre-treatment assessment is non-negotiable.
What do medical societies actually say about enclomiphene?
Only one has issued a formal position, and it is cautious. The British Society of Sexual Medicine published a position statement in 2026 (PMID 41714894) which does not recommend routine use of enclomiphene outside specialist settings. Where it is prescribed, the BSSM says it should be managed by clinicians experienced in male hypogonadism, ideally within research frameworks, and accompanied by counselling about its unlicensed status in the UK. The statement does set out a titration ladder — 6.25 mg daily increasing weekly as tolerated to 25 mg, and up to 50 mg where response is inadequate — which runs higher than the 25 mg ceiling most consumer sources quote. The gap between that measured position and how enclomiphene is marketed online is worth keeping in view.
Does enclomiphene raise estradiol?
Yes, and the common claim that it does not is a misreading of a comparison. What the data show is that enclomiphene raises estradiol LESS than racemic clomiphene does — a 66-patient retrospective found an estradiol change of -5.92 pg/mL on enclomiphene versus +17.50 on clomiphene. That is a relative advantage, and it is real. But against placebo, SERM therapy as a class raised estradiol by a mean 33.99 pg/mL in the 10-RCT meta-analysis. The mechanism makes this unsurprising: enclomiphene works by raising LH, which raises testosterone, and some of that testosterone aromatizes. This is why a sensitive estradiol assay belongs on follow-up labs rather than being skipped on the assumption that the drug is estradiol-neutral.
Is enclomiphene used for post-cycle therapy after anabolic steroids?
It is widely used off-label in PCT contexts to help restart HPG axis function after exogenous androgen use, typically across a 4–8 week course with tapering. The mechanism is the same as in secondary hypogonadism — block estrogen feedback at the hypothalamus, drive LH and FSH back up, restart endogenous testosterone production. The honest caveat is that this use case is not supported by controlled clinical trials; most evidence is observational and anecdotal rather than from RCTs. Competitive athletes should also note that enclomiphene is prohibited by WADA at all times.
Who Enclomiphene Is NOT For
- •Primary hypogonadism (testicular failure) — enclomiphene works by increasing LH/FSH signaling, which is ineffective when the testes cannot respond. Baseline LH/FSH must be checked before starting.
- •Liver disease — clomiphene-class SERMs undergo hepatic metabolism; active significant liver dysfunction is a caution.
- •Known hypersensitivity to clomiphene, enclomiphene, or related triphenylethylenes.
- •Pregnancy — this is a male therapy context, but enclomiphene/clomiphene in female use has defined teratogenic and ovulation-risk considerations and is not appropriate in pregnancy.
- •Active hormone-sensitive malignancy — SERMs have complex tissue-specific agonist/antagonist profiles; use in patients with prostate, breast, or other hormone-sensitive cancers should be oncology-directed rather than general-practice.
- •Pre-existing visual disorders or retinal disease — the clomiphene class has documented visual side effects (shimmering, floaters, rare retinopathy); baseline visual symptoms warrant evaluation before starting.
- •Competitive athletes subject to WADA code — prohibited substance.
Drug & Supplement Interactions
Concurrent exogenous testosterone (TRT): combining enclomiphene with injectable testosterone, gels, or pellets is generally counterproductive — the exogenous testosterone suppresses the HPG axis that enclomiphene is trying to stimulate. Some clinicians use short-term overlap when transitioning off TRT to enclomiphene, but chronic combination is not a coherent strategy. hCG: combining enclomiphene with hCG (which directly stimulates Leydig cells) is sometimes used in fertility-focused protocols. The two act at different points in the axis (hypothalamus vs. testes) and are not mutually exclusive, though the combination should be clinician-managed. Aromatase inhibitors (anastrozole, letrozole): sometimes co-prescribed when estradiol rises substantially on enclomiphene. The combination is common in off-label hormone optimization practice but lacks adequately powered trial data. CYP450-metabolized drugs: enclomiphene is metabolized via CYP2D6 and CYP3A4. Strong inhibitors or inducers of these enzymes can theoretically alter exposure. The clinical significance in typical practice is modest. Anticoagulants: a theoretical interaction exists through hepatic metabolism overlap; INR monitoring is prudent in warfarin users. Beyond these, enclomiphene does not have a large documented panel of clinically significant drug interactions.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a standalone drug
- • Available through compounding pharmacies — quality varies by source
- • Monitoring testosterone, estradiol, LH, FSH, and hematocrit recommended
- • Contraindicated in primary hypogonadism (testicular failure)
- • Banned by WADA — prohibited in competitive sports
- • A first-of-its-kind 2026 case report described newly detected atrial flutter after enclomiphene dose escalation (Tariq et al., Cureus, PMID 42741668) — a signal to weigh in patients with cardiovascular risk factors and to consider on new-onset palpitations
What We Don't Know
Long-term safety data beyond 3 years is limited. Whether enclomiphene provides the same cardiovascular, bone density, and metabolic benefits as testosterone replacement is unclear. The compounding pharmacy supply chain lacks the quality controls of FDA-approved manufacturing.
Legal Status
United States
Enclomiphene is not FDA-approved as a standalone drug. Racemic clomiphene (Clomid) is FDA-approved for female ovulation induction. Enclomiphene is available through state-licensed 503A compounding pharmacies under individualized prescription. Enclomiphene citrate is in FDA's 503A category 1 (bulk drug substances under evaluation) on the May 14, 2026 list; FDA does not intend to take action against compounding with category 1 substances, provided the conditions in its interim-policy guidance are met, until it decides whether to add the substance to the 503A bulks list. Use in men is off-label. It is not a controlled substance.
International
Regulatory treatment varies. Clomiphene is broadly approved for female ovulation induction across most jurisdictions; pure enclomiphene is not a separately approved product in major markets. Availability for male use typically runs through compounding or international pharmacy channels with variable legal status.
Sports & Competition
Enclomiphene and clomiphene are prohibited by WADA at all times (in and out of competition) under class S4.2 (anti-estrogenic substances, within S4 Hormone and Metabolic Modulators), which names clomifene; enclomiphene is clomiphene's trans-isomer. Competitive athletes subject to WADA, USADA, UKAD, or equivalent anti-doping authorities must not use either compound. One procedural nuance is worth knowing: substances in classes S4.1 and S4.2 are Specified Substances, which does not make them any less prohibited but does give tribunals more latitude on sanction length where an athlete can establish how the substance entered their system. Therapeutic Use Exemptions can be requested but are assessed case by case.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Enclomiphene is a peptide.
Reality
It is not. Enclomiphene is a small-molecule triphenylethylene SERM — structurally related to tamoxifen — and is functionally and chemically distinct from peptide therapeutics. This site covers it because it is discussed constantly in peptide and hormone-optimization circles, but the chemistry is small molecule, not peptide.
Myth
Enclomiphene is FDA-approved for male hypogonadism.
Reality
It is not. The Androxal program received a Complete Response Letter from the FDA in 2015 and was subsequently discontinued in 2021. Current availability is through compounding pharmacies, and all male use is off-label. Racemic clomiphene is FDA-approved for female ovulation induction only.
Myth
Enclomiphene is equivalent to TRT, just taken as a pill.
Reality
The endocrine effect is different. TRT delivers exogenous testosterone and suppresses endogenous HPG axis function, reducing intratesticular testosterone and sperm production. Enclomiphene stimulates the HPG axis to produce more endogenous testosterone, preserving fertility and testicular function. The downstream outcomes — cardiovascular, bone density, long-term safety — are not yet proven equivalent.
Myth
Enclomiphene works for any low-testosterone man.
Reality
It only works in secondary hypogonadism (low testosterone with low or inappropriately normal LH/FSH). In primary hypogonadism (low testosterone with elevated LH/FSH indicating testicular failure), the testes cannot respond to the elevated gonadotropin signal, and enclomiphene will not meaningfully raise testosterone. Baseline LH/FSH is the critical pre-treatment assessment.
Myth
Enclomiphene has no side effects because it is 'cleaner' than clomiphene.
Reality
It is cleaner — removing zuclomiphene eliminates much of the estrogenic accumulation and associated mood and visual effects. But it is not side-effect-free. Headache, hot flashes, mild nausea, and modest estradiol rise occur. Rare visual effects (shimmering, floaters) from the class still warrant monitoring. WADA prohibits it for competitive athletes.
Published Research
15 studiesNewly Detected Atrial Flutter After Enclomiphene Dose Escalation in a Patient With Prior Mitral Valve Repair and Chronic Immune Thrombocytopenia: A Case Report.
Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives.
Clomiphene citrate versus testosterone replacement therapy in male hypogonadism: a systematic review of literature and meta-analysis.
Constantinou et al., Eur J Clin Pharmacol, July 2026 — 11 studies and 1,512 men comparing clomiphene citrate with testosterone replacement. Pooled serum testosterone showed no significant difference between clomiphene and TRT overall (MD 6.64 ng/dL, 95% CI -35.35 to 48.63), with injectable testosterone outperforming clomiphene in the single study that tested it and gel-based TRT showing no difference. The finding most relevant to the choice is on symptoms rather than hormones: post-treatment libido scores were LOWER with clomiphene than TRT (MD -0.54, 95% CI -0.87 to -0.21, p=0.009). Note this review studied racemic clomiphene, not enclomiphene, and measured testosterone and libido — it reports no cardiovascular, bone or metabolic endpoints.
Clomiphene Citrate in off-Label Post-Cycle Therapy: Mechanisms, Efficacy and Diagnostic Challenges in Endocrine Recovery Following Anabolic Steroid Use.
Testosterone Versus Clomiphene Treatment of Hypogonadism: A Retrospective Analysis in US Veterans.
British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism.
Foster et al., World Journal of Men's Health 2026 — the only national society position statement on enclomiphene, and a notably cautious one. The BSSM does not recommend routine use outside specialist settings, and states that where it is prescribed it should be managed by clinicians experienced in male hypogonadism, ideally within research frameworks, with explicit counselling about its unlicensed status in the UK. It also sets out a titration ladder that runs higher than most consumer sources: start at 6.25 mg daily and increase weekly as tolerated to 25 mg, with a further increase to 50 mg daily if the clinical or biochemical response is inadequate.
Comment on Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.
Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.
10 RCTs, 819 patients, +274 ng/dL testosterone
Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.
Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications.
Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study.
Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.
Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism.
Enclomiphene citrate for the treatment of secondary male hypogonadism.
Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics.
Wiehle and Cunningham, BJU International 2013 — the foundational enclomiphene trial, and the source of the dose range the whole field uses. A randomized, single-blind, two-centre Phase II study in 48 men with secondary hypogonadism compared enclomiphene citrate at 6.25, 12.5 and 25 mg daily against transdermal testosterone (AndroGel), measuring 24-hour luteinizing hormone and total testosterone profiles. It is the study behind every 12.5-to-25 mg protocol discussed today, and the clearest demonstration that enclomiphene raises testosterone while raising rather than suppressing LH.
Quick Facts
- Class
- Selective Estrogen Receptor Modulator
- Tier
- B
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- Nov 2026
- Citations
- 15PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.